NasdaqCM - Nasdaq Real Time Price USD

Clearmind Medicine Inc. (CMND)

0.9900
+0.0200
+(2.06%)
At close: May 16 at 4:00:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for CMND

Recent News: CMND

View More
Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
GlobeNewswire 7 days ago
Psychedelic: Clearmind completes clinical site initiations for AUD trial

Psychedelic: Clearmind completes clinical site initiations for AUD trial
TipRanks 23 days ago
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
GlobeNewswire 23 days ago
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
GlobeNewswire 23 days ago
Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
GlobeNewswire 25 days ago
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
GlobeNewswire 27 days ago
Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
GlobeNewswire last month
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
GlobeNewswire last month
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial

Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
TipRanks last month
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
GlobeNewswire last month
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
GlobeNewswire last month
View More

Related Tickers

SPRC SciSparc Ltd.
0.3159
+3.24%
 
PXMD PaxMedica, Inc.
0.0001
0.00%
 
DRMA Dermata Therapeutics, Inc.
0.7910
-0.38%
 
ZVSA ZyVersa Therapeutics, Inc.
0.5229
-0.21%
 
BPTH Bio-Path Holdings, Inc.
0.1850
+2.78%
 
ACRV Acrivon Therapeutics, Inc.
1.1500
+4.55%
 
GHRS GH Research PLC
10.98
+2.62%
 
APLM Apollomics, Inc.
4.8900
+3.60%
 
CDIO Cardio Diagnostics Holdings, Inc.
3.8400
-4.00%
 
INAB IN8bio, Inc.
0.1287
-2.87%